Expired activity
Please go to the PowerPak
homepage and select a course.
Improving the Treatment of Dry Eye Disease: An Update for Pharmacists
Jointly provided by Postgraduate Institute for Medicine (www.pimed.com) and MedEdicus LLC
This activity is supported by an independent educational grant from Shire.
Release date
May 2, 2018
Expiration date
May 31, 2019
Estimated time to complete activity
2.0 hours
Target Audience
This activity is intended for pharmacists engaged in the care of patients with dry eye disease.
eDUCATIONAL Objectives
After completing this activity, the participant should be better able to:
- Identify the key features of the pathophysiology of DED
- Evaluate risk factors for the development or exacerbation of DED when counseling patients on pharmacologic matters
- Describe the safety, efficacy, and administration of current medical treatments for DED
Faculty
Elizabeth Yeu, MD (Co-Chair)
Assistant Professor of Ophthalmology
Eastern Virginia Medical School
Corneal, Cataract, and Refractive Surgeon
Partner, Virginia Eye Consultants
Norfolk, Virginia
Catherine A. Opere, BPharm, MBA, PhD (Co-Chair)
Professor
School of Pharmacy and Health Professions
Creighton University
Omaha, Nebraska
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and MedEdicus. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 2 contact hour(s) (0.2 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-18-060-H01-P)
Type of Activity
Knowledge
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
FACULTY
| Name of Faculty or Presenter |
Reported Financial Relationship |
| Catherine A. Opere, BPharm, MBA, PhD |
Has no real or apparent conflicts of interest to report |
| Elizabeth Yeu, MD |
Consulting Fees (e.g., advisory boards): Abbott Medical Optics; Alcon; Allergan; Bausch & Lomb Incorporated; Bio-Tissue; i-Optics; Ocular Science; Ocular Therapeutix, Inc; Shire; TearLab Corporation; TearScience; and Valeant
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents (e.g., speakers' bureaus): Abbott Medical Optics; Alcon; Allergan; and TearLab Corporation
Ownership Interest (stocks, stock options, or other ownership interest excluding diversified mutual funds): Modernizing Medicine; and Strathspey Crown |
Planners and Managers
The PIM planners and managers have nothing to disclose. The MedEdicus planners and managers have nothing to disclose.
Method of Participation and INSTRUCTIONS for Credit
During the period May 2, 2018, through May 31, 2019, participants must 1) read the learning objectives and disclosures; 2) study the educational activity; and 3) complete the post-test with a score of 75% or better and the activity evaluation. Once you complete the online evaluation, your certificate will be made available immediately. Click on View Certificate and print the certificate for your records.
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Unlabeled Use
This educational activity might contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
System Requirements for Digital Edition
Please ensure the computer you plan to use meets the following requirements:
- Operating System: Windows or Macintosh
- Media Viewing Requirements: Flash Player or Adobe Reader
- Supported Browsers: Microsoft Internet Explorer, Firefox, Google Chrome, Safari, and Opera
- A good Internet connection
Policy on Privacy and Confidentiality
For information about the activity, please contact Postgraduate Institute for Medicine (www.pimed.com) 1-800-423-3576 or email to inquiries@pimed.com.
